1stOncology™: Cancer Intelligence Service – Page 12454 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Jazz Pharmaceuticals to Report 2019 Fourth Quarter and Full Year Financial Results on February 25, 2020

On February 11, 2020 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) reported that it will report its 2019 fourth quarter and full year financial results on Tuesday, February 25, 2020, after the close of the financial markets (Press release, Jazz Pharmaceuticals, FEB 11, 2020, View Source [SID1234554184]). Company management will host a live audio webcast immediately following the announcement at 4:30 p.m. EST/9:30 p.m. GMT to discuss fourth quarter and full year 2019 financial results and provide a business and financial update and guidance for 2020 financial results.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary to listen to the webcast. A replay of the webcast will be archived on the website for at least one week.

Penumbra, Inc. Schedules Fourth Quarter and Full Year 2019 Earnings Release and Conference Call for February 25, 2020

On February 11, 2020 Penumbra, Inc. (NYSE: PEN) reported that it will host a conference call to discuss financial results for the fourth quarter and full year 2019 after market close on Tuesday, February 25, 2020 at 5:00 PM Eastern Time (Press release, Penumbra, FEB 11, 2020, View Source [SID1234554183]). A press release with fourth quarter and full year 2019 financial results will be issued after market close that day.

Webcast & Conference Call Information
The conference call can be accessed live over the phone by dialing (833) 227-5837 for domestic callers or (647) 689-4064 for international callers (conference id: 3899277), or the webcast can be accessed on the "Events" section under the "Investors" tab of the Company’s website at: www.penumbrainc.com. The webcast will be available on the Company’s website for at least two weeks following the completion of the call.

Theravance Biopharma Announces Pricing of Public Offering of Ordinary Shares

On February 11, 2020 Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company"), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, reported the pricing of its underwritten public offering of 5,500,000 ordinary shares at a price to the public of $27.00 per share (Press release, Theravance, FEB 11, 2020, View Source [SID1234554182]). The gross proceeds to Theravance Biopharma from the offering are expected to be approximately $148.5 million, before deducting underwriting discounts and commissions and estimated offering expenses. In addition, Theravance Biopharma has granted the underwriters a 30-day option to purchase up to an additional 825,000 ordinary shares at the public offering price, less underwriting discounts and commissions. The offering is expected to close on February 14, 2020, subject to customary closing conditions.

Morgan Stanley, J.P. Morgan and Cowen are acting as the joint book-running managers for the offering. Credit Suisse, Cantor and Needham & Company are acting as co-managers for the offering.

A shelf registration statement (including a base prospectus) relating to the shares was filed with the SEC and is effective. A preliminary prospectus supplement related to the offering has been filed with the SEC and will be available on the SEC’s website located at View Source Copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering may be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 2nd Floor, 180 Varick Street, New York, New York 10014, United States of America, J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by calling 1-866-803-9204, or by email at [email protected]; or Cowen and Company, LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, by calling 1-(833) 297-2926, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

Volastra Therapeutics Launches with $12 Million in Seed Financing to Develop Novel Metastatic Cancer Therapies

On February 11, 2020 Volastra Therapeutics, a biotechnology company developing novel therapies for the treatment of metastatic cancers, reported with a $12 million financing (Press release, Volastra Therapeutics, FEB 11, 2020, View Source [SID1234554181]). Polaris Partners led the financing with additional investment from DROIA Oncology Ventures, the Global Health Sciences (GHS) Fund (Quark Venture LP and GF Securities), and ARCH Venture Partners.

The company will focus on developing therapies for metastatic cancers by targeting key pathways related to chromosomal instability, a hallmark of cancer metastasis. The majority of oncology therapeutics target alterations widely found in primary tumors while metastasis is responsible for approximately 90% of cancer deaths. Volastra hopes to change the treatment paradigm for patients by developing novel therapeutics specifically tailored to advanced disease.

Founded by Drs. Lewis Cantley, Samuel Bakhoum, and Olivier Elemento, the company’s technology and scientific approach is based on pioneering science from the Cantley and Elemento Labs at Weill Cornell Medicine in collaboration with the Bakhoum Lab at Memorial Sloan Kettering Cancer Center.

"At Volastra, we address the pathways not only driving chromosomal instability in metastatic cancers, but also those pathways that are impaired by the genomic chaos that is a precursor of tumor progression," said Dr. Cantley, Professor of Cancer Biology in Medicine and Meyer Director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medical College.

The company also will utilize an extensive library of organoids derived from metastatic cancer samples to elucidate how tumors spread and devise therapeutic strategies that target chromosomal instability during the process of cancer metastasis. This platform enables Volastra to perform rigorous target validation, to advance first-in-class clinical candidates, and to identify biomarkers to stratify patients for clinical trials.

Executive Chair Sandra Peterson, a Partner at Clayton, Dubilier, and Rice, a Board Member of Microsoft, and the former Group Worldwide Chairman of Johnson & Johnson, will lead the Volastra Board of Directors. Polaris Managing Partner Amy Schulman will serve alongside Ms. Peterson on the company’s Board of Directors with DROIA Partner Luc Dochez and GHS Fund CSO and Partner Zafi Avnur. Dr. Bakhoum will represent the scientific founders on the company’s Board.

"With the revolutionary insights into tumor biology, the scientific expertise of the founders and an experienced management team coming together, Volastra Therapeutics is uniquely positioned to shift the treatment paradigm in oncology," said Ms. Schulman of Polaris. "Together we are committed to fundamentally changing the way that patients with metastatic cancer are treated."

Dana-Farber Cancer Institute Provides State-of-the-Art Oncology Support Services to Kronos Employees Through New Company Benefit

On February 11, 2020 Dana-Farber Cancer Institute and Kronos Incorporated reported that they have joined forces to provide dedicated oncology care navigation services via a new benefit for Kronos employees and their beneficiaries (Press release, Dana-Farber Cancer Institute, FEB 11, 2020, View Source [SID1234554180]). As part of the Dana-Farber Direct Connect program, each patient receives patient navigation assistance, highly specialized clinical care, and an expert team providing a multi-disciplinary approach to care that encompasses the full continuum of their oncology journey. Kronos, a global leader in workforce management and human capital management cloud solutions known worldwide for its award-winning WorkInspired culture, is the first employer to provide its employees with the Dana-Farber Direct Connect benefit.

Through this innovative program, Dana-Farber Direct Connect provides companies with dedicated support services for their employees and is proud to align with an organization like Kronos known for a culture steeped in caring for its employees, their families, and the communities where Kronos employees live and work. All Kronos employees and beneficiaries enrolled in the benefit will have access to a dedicated phone line and email that is staffed by experienced liaisons who are trained to support the unique needs of each patient and can help identify the right treatment options, facilitate appointments, and access support services based on the cancer type and the individual’s specific needs. Dana-Farber’s specialized treatment centers are comprised of teams of experts who work closely together to provide patients the latest therapies and strategies, including access to innovative clinical trials, integrative medicine services, stem-cell transplants, cell therapies, and immunotherapy.

"Finding out that you or someone you care about has cancer is a devastating and life-altering experience. There are so many questions to be answered – everything from, ‘Where can I find the best doctors?’ to ‘What does my insurance cover?’ Managing treatment, doctor visits, and billing can quickly become a full-time job when the patient’s focus and effort should be spent healing and fighting. By formalizing this new benefit with Dana-Farber Direct Connect, Kronites and their family members will have special access to top oncology doctors in Massachusetts along with all the support resources that the world-class Dana-Farber Cancer Institute has to offer," said David Almeda, Chief People Officer at Kronos.

In addition to helping all patients at a challenging time, Dana-Farber Direct Connect aims to:

reduce the variability in misdiagnosis
improve cancer outcomes, care, and experience for all patients across the country
assist employers in reducing health care costs by ensuring the right treatment, at the right time with coordinated care to improve outcomes
"We are pleased to work closely with Kronos to provide their employees and family members access to the exceptional patient care that Dana-Farber is known for and to work together on initiatives that will reduce health care costs," said James Terwilliger, Chief Operating Officer and Executive Vice President at Dana-Farber Cancer Institute. "Oncology care is complex, with advances in treatment and drug options being made at dramatic pace. The Dana-Farber Direct Connect program ensures that the best care and treatment options are offered to each patient so that they can focus on getting healthy."